Skip to main content

Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose

NIDA - National Institute on Drug Abuse

open
OpenLast verified: 2026-06-19

About This Grant

Project Abstract This project focuses on the development of long-acting opioid antagonist, mixed agonist-antagonist, and agonist nanoparticle formulations for the treatment of overdose, reduction of opioid withdrawal, and prevention of renarcotization from fentanyl and fentanyl analogs (F/FAs), including carfentanil. These compounds are extremely potent mu opioid receptor (MOR) agonists that are easy to manufacture in clandestine laboratories and used as adulterants in counterfeit prescription medications and illicit street mixtures. Because of their widespread availability, F/FAs are responsible for over 70% of overdose deaths in the US. While antagonists like naloxone and nalmefene are FDA approved to treat opioid overdose, they can precipitate severe opioid withdrawal and may be insufficient to prevent toxicity and renarcotization in accidental F/FA overdoses. Renarcotization occurs when the antagonist effects wear off and the respiratory depressive effects of the opioid return due to differences in elimination half-lives. Management of overdoses involving F/FA is complex, often requiring intensive acute medical care and extended observation of patients. To reverse fentanyl-induced respiratory depression and prevent fentanyl effects out to 48 hours, our group has developed a novel long-acting naloxone nanoparticle (cNLX-NP). This project will focus on further development of this naloxone nanoparticle as well as development of other antagonist formulations (nalmefene and naltrexone), mixed agonist-antagonist (MAA) formulations (buprenorphine, nalbuphine, and butorphanol), and an agonist formulation (desmetramadol). The specific aims of the project are Aim 1: Develop antagonist nanoparticles, determine the lowest effective doses of each nanoparticle, and test whether antagonist nanoparticles induce anhedonia or precipitate opioid withdrawal via somatic signs; Aim 2: Develop MAA and agonist nanoparticles, determine the lowest effective doses, test whether MAA and agonist nanoparticles elicit rewarding, antinociceptive, or anhedonic effects, and test whether these nanoparticles precipitate opioid withdrawal; Aim 3: The 3 most effective formulations will be further characterized by determining the highest F/FA doses that each formulation is effective against, testing efficacy out to 120 hours, testing efficacy against a combination of fentanyl and alprazolam, test the efficacy in animals chronically exposed to fentanyl, characterize the pharmacokinetics of the lead formulation, and determine whether these formulations (which include a mixture with free naloxone) precipitate opioid withdrawal in rats using intracranial self-stimulation.

Grant Summary

Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose is a NIDA - National Institute on Drug Abuse grant providing up to $723K for university, nonprofit, healthcare org. Applications are due 2031-03-31 (open). Check eligibility and apply with FindGrants.

Focus Areas

health research

Eligibility

universitynonprofithealthcare org

How to Apply

Funding Range

Up to $723K

Deadline

2031-03-31

Complexity
High
  1. 1Confirm your organization is eligible for Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose from NIDA - National Institute on Drug Abuse, checking organization type, location, and any population or project requirements.
  2. 2Gather the required documents and information, including your organization details, project plan, and budget figures.
  3. 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
  4. 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIDA - National Institute on Drug Abuse before the deadline.
This record is a past award, contract, or funder profile — useful for research, but not an open grant application. Check the original source for current opportunities from this funder.

Don't want to draft it yourself?

We'll draft the complete application against NIDA - National Institute on Drug Abuse's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.

AI Requirement Analysis

Detailed requirements not yet analyzed

Have the NOFO? Paste it below for AI-powered requirement analysis.

0 characters (min 50)

Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose: Frequently Asked Questions

Who is eligible for the Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose?

Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose is offered by NIDA - National Institute on Drug Abuse and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.

How much funding does the Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose provide?

Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose provides up to $723K per award from NIDA - National Institute on Drug Abuse. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.

When is the Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose deadline?

Applications for Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose are due 2031-03-31 (open). Because deadlines can change, verify the date with the funder, NIDA - National Institute on Drug Abuse, and give yourself enough time to prepare a complete, competitive application before the close date.

How do you apply for the Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose?

To apply for Long-acting nanoparticle antidotes for the treatment of synthetic opioid overdose, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIDA - National Institute on Drug Abuse.

Browse More Grants